BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 05, 2026 |
Jul. 17, 2024 |
Apr. 30, 2026 |
Mar. 31, 2026 |
Feb. 28, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | $ 1,169,441 | $ 1,059,708 | ||||||||||
| Number of warrants issued | 2,800,000 | 7,950,000 | 6,250,000 | |||||||||
| Cash on hand | $ 2,336,022 | 2,336,022 | $ 1,558,525 | |||||||||
| Net of operating activities | (1,169,441) | (1,059,708) | ||||||||||
| Inventory | 56,427 | 56,427 | 57,257 | |||||||||
| Research and development costs | $ 49,182 | $ 107,965 | $ 87,105 | $ 227,246 | ||||||||
| Intellectual Property [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Finite lived intangible asset useful life | 10 years | 10 years | ||||||||||
| Finite lived intangible asset amortization period | 10 years | 10 years | ||||||||||
| Maximum [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Useful lives of assets | 5 years | 5 years | ||||||||||
| Regulation A+ Offerings [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Value of shares issuable | $ 60,000,000 | |||||||||||
| Sale of stock value | $ 75,000,000.0 | |||||||||||
| Number of common stock shares issued, value | $ 2,203,800 | $ 2,203,800 | $ 1,500,000 | $ 2,266,000 | $ 1,179,245 | |||||||
| Number of common stock shares issued, shares | 27,200,000 | 27,200,000 | 12,500,000 | 12,500,000 | 24,950,000 | 16,132,000 | ||||||
| Private Placement [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Number of warrants issued | 27,800,000 | 27,800,000 | 6,250,000 | 18,797,000 | ||||||||
| Value of warrants issued | $ 6,250 | |||||||||||
| Brachytherapy Product Line [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | $ 3,000,000 | |||||||||||
| Net of operating activities | (3,000,000) | |||||||||||
| Radionuclide Therapy Product Line [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | (3,000,000.0) | |||||||||||
| Net of operating activities | $ 3,000,000.0 | |||||||||||
| Offering term, description | Over the next 36 months, the Company believes it will require approximately $9.0 million in additional capital to: (i) fund the FDA approval process and related activities to conduct human clinical trials; (ii) conduct Phase I, pilot, and other clinical trials; (iii) activate several regional clinics to administer IsoPet® across the United States; (iv) create an independent production center within the current production site to serve as a template for future international manufacturing; and (v) initiate regulatory approval processes outside of the United States. | |||||||||||